**Supplementary Table 1. The correlation between lncRNA GMDS-AS1 expression and clinicopathological characteristics in lung adenocarcinoma patients.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Clinicopathological characteristics** | **Cases (n)** | **GMDS-AS1 expression** | | ***P* value** |
|  |  | **High** | **Low** |  |
| Age (years) |  |  |  |  |
| >60 | 13 | 8 | 5 | 0.4621 |
| ≤60 | 17 | 7 | 10 |  |
| Gender |  |  |  |  |
| Female | 9 | 6 | 3 | 0.4270 |
| Male | 21 | 9 | 12 |  |
| Tumor size (cm) |  |  |  |  |
| >5 cm | 11 | 3 | 8 | 0.1281 |
| ≤5 cm | 19 | 12 | 7 |  |
| Lymph node metastasis |  |  |  |  |
| Yes | 14 | 2 | 12 | 0.0007 |
| No | 16 | 13 | 3 |  |
| Smoking status |  |  |  |  |
| Yes | 20 | 14 | 6 | 0.0052 |
| No | 10 | 1 | 9 |  |
| TNM stage |  |  |  |  |
| I-II | 8 | 5 | 3 | 0.6817 |
| III-IV | 22 | 10 | 12 |  |

**Supplementary Table 2. Primers of quantitative reverse transcription PCR.**

|  |  |
| --- | --- |
| LncRNA GMDS-AS1 | Forward: 5’-CAGGATTGAGGGGCTTCTCC-3’ |
| Reverse: 5’-CATCTTCCAGGCCAAATGCC-3’ |
| SIRT1 | Forward: 5’-CAGTGGCTGGAACAGTGAGA-3’ |
| Reverse: 5’-TCTGGCATGTCCCACTATCA-3’ |
| TAF15 | Forward: 5’-TGACCAGCAGTCAGGCTATG-3’ |
| Reverse: 5’-TCACATCACGACGGTCATCT-3’ |
| GAPDH | Forward: 5’-CCAGGTGGTCTCCTCTGA-3’ |
| Reverse: 5’-GCTGTAGCCAAATCGTTGT-3’ |